Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
1 finding from 1 review
Back pain · Patients with ankylosing spondylitis
1 finding from 1 review
Disease activity · Patients with ankylosing spondylitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean improvement in Bath ankylosing spondylitis function index (BASFI) ‐ not reported · Patients with ankylosing spondylitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean improvement in Bath ankylosing spondylitis metrology index (BASMI) ‐ not reported · Patients with ankylosing spondylitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiographic progress ‐ not reported · Patients with ankylosing spondylitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with ankylosing spondylitis
Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with ankylosing spondylitis
Sulfasalazine showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Induction of remission (CDAI <150), therapeutic response (VHI decrease >=25%) or clinical improvement · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150), therapeutic response (VHI… compared with placebo (low certainty).
1 finding from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine showed no clear difference in induction of remission (CDAI <150) (Random Effects Model) compared with placebo (moderate certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
1 finding from 1 review
Maintenance of remission · Maintenance of remission in ulcerative colitis
It is very uncertain whether methotrexate + sulfasalazine changes maintenance of Remission compared with sulfasalazine (very low certainty).
1 finding from 1 review
Intervention not reported
Sulfasalazine (2 RCTs; 143 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes sulfasalazine (2 RCTs; 143 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Sulfasalazine + prednisolone (1 RCT; 57 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes sulfasalazine + prednisolone (1 RCT; 57 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Sulfasalazine (1 RCT; 32 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes sulfasalazine (1 RCT; 32 participants) (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found